Clinical trial · Observational
Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Immune Response Under Immunotherapy in Metastatic Non-Small Cell Lung Cancer: Sputum, Blood Samples and Microbiota Study
NCT04804137CI-TRIAL-00073062RICEPScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective pathophysiological exploratory monocentric study, focusing on adult patients with non-small cell lung cancer (NSCLC) : non-squamous type without oncogenic addiction, metastatic, treated with immune checkpoint inhibitors alone or in combination with chemotherapy in front line at the CHRU de Tours, France.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Non-squamous Lung Cancer | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood | Other | — | UNRESOLVED |
| saliva | Other | — | UNRESOLVED |
| sputum | Other | — | UNRESOLVED |
| stool | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group
- description
- adult patients with adenocarcinoma type non-small cell lung cancer
- interventionNames
- Other: Blood
- Other: sputum
- Other: saliva
- Other: stool
Primary outcomes (2)
- measure
- Immune and inflammatory response in the blood
- timeFrame
- 30 months
- description
- * T cell sub populations assessed by their relative abundance, and will be expressed as a percentage of total T cells * B lymphocytes * Cytokine inflammatory profile: the level of activation/regulation, production of cytokines and cytotoxicity markers will be analysed as a percentage of cells expressing the markers or producing the cytokines in relation to the total cell population (e.g. HLA-DR+, CD38+, Bcl-2lo phenotype of CD8 T lymphocytes)
- measure
- Immune and inflammatory response in the airways
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 18 years or over * Diagnosis of metastatic NSCLC (Stage IV) adenocarcinoma only * Absence of oncogenic addiction (EGFR, ALK, ROS1, RET, MET, BRAF) * Treatment with ICI anti-PD1 or anti-PDL1 (pembrolizumab or atezolizumab) as 1st line treatment alone or in combination with chemotherapy and/or anti-angiogenic (bevacizumab). * 1st injection of ICI, whether or not combined with chemotherapy Exclusion Criteria: * Patient under judicial protection * Pregnant or breastfeeding women * NSCLC of the epidermal or undifferentiated type * Opposition to data processing
References
Publications (0)
Data not yet available
No reference posted for this study.